Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Go back to Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid TumorsSurf A Movie Solutions, Inc. (NASDAQ: SURF) | Delayed: 1.07 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $1.07 | 52 Week High | $0.42 | |||
Open | $1.07 | 52 Week Low | $0.42 | |||
Day High | $1.07 | P/E | N/A | |||
Day Low | $1.07 | EPS | $-0.01 | |||
Volume | 19,118 |